Stocktoria
Jasper Therapeutics, Inc. JSPR
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2019-11-20
Jasper Therapeutics, Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| R&D expense | $63.1M | $55.8M | $51.8M | $34.6M | $25.4M |
| Operating income | -$83.9M | -$76.2M | -$68.9M | -$51.2M | -$36.8M |
| Income tax | — | $2,000 | $2,000 | — | — |
| Net income | -$75.8M | -$71.3M | -$64.5M | -$37.7M | -$30.6M |
| EPS (diluted) | $-3.95 | $-4.89 | $-6.18 | $-10.33 | $-2.69 |
| Operating cash flow | -$77.2M | -$62.6M | -$52.1M | -$45.9M | -$33.7M |
| Cash & equivalents | $28.7M | $71.6M | $86.9M | $38.2M | $84.7M |
| Total assets | $35.8M | $79.9M | $94.9M | $48.4M | $93.7M |
| Total liabilities | $31.6M | $18.2M | $16.5M | $12.4M | $24.1M |
| Shareholders' equity | $4.2M | $61.7M | $78.4M | $36.0M | $69.5M |
Source: SEC EDGAR filings · CIK 0001788028 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.